Fonte: Scientific reports. Unidade: FM
Assuntos: MIÓCITOS DE MÚSCULO LISO, RATOS
ABNT
SANTOS, Danúbia Silva dos et al. Empagliflozin reduces arrhythmogenic effects in rat neonatal and human iPSC-derived cardiomyocytes and improves cytosolic calcium handling at least partially independent of NHE1. Scientific reports, v. 13, n. 1, 2023Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/54875. Acesso em: 12 out. 2024.APA
Santos, D. S. dos, Turaça, L. T., Coutinho, K. C. da S., Barbosa, R. A. Q., Kasai-Brunswick, T. H., Carvalho, A. C. C. de, et al. (2023). Empagliflozin reduces arrhythmogenic effects in rat neonatal and human iPSC-derived cardiomyocytes and improves cytosolic calcium handling at least partially independent of NHE1. Scientific reports, 13( 1). doi:10.1038/s41598-023-35944-5NLM
Santos DS dos, Turaça LT, Coutinho KC da S, Barbosa RAQ, Kasai-Brunswick TH, Carvalho ACC de, Girardi ACC, Polidoro JZ. Empagliflozin reduces arrhythmogenic effects in rat neonatal and human iPSC-derived cardiomyocytes and improves cytosolic calcium handling at least partially independent of NHE1 [Internet]. Scientific reports. 2023 ; 13( 1):[citado 2024 out. 12 ] Available from: https://observatorio.fm.usp.br/handle/OPI/54875Vancouver
Santos DS dos, Turaça LT, Coutinho KC da S, Barbosa RAQ, Kasai-Brunswick TH, Carvalho ACC de, Girardi ACC, Polidoro JZ. Empagliflozin reduces arrhythmogenic effects in rat neonatal and human iPSC-derived cardiomyocytes and improves cytosolic calcium handling at least partially independent of NHE1 [Internet]. Scientific reports. 2023 ; 13( 1):[citado 2024 out. 12 ] Available from: https://observatorio.fm.usp.br/handle/OPI/54875